METHOD OF REDUCING BISPECIFIC T CELL ENGAGER OR CHIMERIC ANTIGEN RECEPTOR T CELL MEDIATED CYTOKINE RELEASE SYNDROME USING INTERLEUKINS-4, -10, OR A FUSION PROTEIN THEREOF

1 . A method of reducing the severity of bispecific T cell engager (BiTE) or chimeric antigen receptor T cell (CAR-T) therapy induced cytokine release syndrome (CRS) during malignant disease treatment and enhancing tumor cytolysis comprising administering to a patient in need thereof an amount of a composition comprising a dual cytokine fusion protein of Formula II

wherein

“Y” is a monomer of IL10 or an variant thereof;

“X 1 ” is a VL or VH region from a first monoclonal antibody;

“X 2 ” is a VH or VL region from the first monoclonal antibody;

wherein when X 1 is a VL, X 2 is a VH or when X 1 is a VH, X 2 is a VL,

wherein the first monoclonal antibody is an anti-ebola antibody;

wherein the VL and VH from the anti-ebola antibody include 3 light chain CDRs and 3 heavy chain CDRs that are engrafted with 3 light chain CDRs and 3 heavy chain CDRs from a second monoclonal antibody;

“Z” is a cytokine other than IL-10;

“n” is an integer of 1; and

wherein:

i. the IL-10 is SEQ ID No: 1, the second antibody is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and Z is IL-2;

ii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-15;

iii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-7;

iv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-28;

v. the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-29;

vi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and Z is IFN-α;

vii, the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and

viii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-2;

ix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-15;

x. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-7;

xi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-28;

xii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-29;

xiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IFN-α;

xiv, the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-21;

xv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-2;

xvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-15;

xvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-7;

xviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-28;

xix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-29;

xx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IFN-α;

xxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-21;

xxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-2;

xxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and

xxiv, the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-7;

xxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-28;

xxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-29;

xxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IFN-α;

xxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-21;

xxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-2;

xxx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-15;

xxxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-7;

xxxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-28;

xxxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-29;

xxxiv, the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IFN-α;

xxxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-21;

xxxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-2;

xxxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-15;

xxxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-7;

xxxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and

xl. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-29;

xli. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IFN-α;

xlii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-21;

xliii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-2;

xliv, the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-15;

xlv the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-7;

xlvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-28;

xlvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-29;

xlviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IFN-α;

xlix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-21;

I. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-2;

Ii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-15;

Iii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-7;

Iiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-28;

Iiv, the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-29;

Iv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IFN-α;

Ivi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-21;

Ivii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-2;

Iviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-15;

Iix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-7;

Ix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-28;

Ixi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-29;

Ixii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IFN-α;

Ixiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-21;

Ixiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-2;

Ixv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-15;

Ixvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-7;

Ixvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-28;

Ixviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-29;

Ixix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IFN-α;

Ixx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-21;

Ixxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-2;

Ixxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-15;

Ixxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-7;

Ixxiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-28;

Ixxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-29;

Ixxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IFN-α;

Ixxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-21;

Ixxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-2;

Ixxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-15;

Ixxx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-7;

Ixxxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-28;

Ixxxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-29;

Ixxxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IFN-α;

Ixxxiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-21;

Ixxxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-2;

Ixxxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-15;

Ixxxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and

xxxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-28;

Ixxxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-29;

xc. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IFN-α;

xci. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-21;

xcii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-2;

xciii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-15;

xciv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-7;

xcv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-28;

xcvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-29;

xcvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IFN-α;

xcviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-21;

xcix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-2;

c. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-15;

ci. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-7;

cii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-28;

ciii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and

civ. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IFN-α;

cv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-21;

cvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-2;

cvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-15;

cviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-7;

cix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-28;

cx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-29;

cxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IFN-α;

cxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-21;

cxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-2;

cxiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-15;

cxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-7;

cxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-28;

cxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-29;

cxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IFN-α;

cxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-21;

cxx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-2;

cxxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-15;

cxxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-7;

cxxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-28;

cxxiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-29;

cxxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IFN-α;

cxxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-21;

cxxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-2;

cxxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-15;

cxxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-7;

cxxx. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-28;

cxxxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-29;

cxxxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IFN-α;

cxxxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-21;

cxxxiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-2;

cxxxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and

cxxxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-7;

cxxxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-28;

cxxxviii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-29;

cxxxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IFN-α;

cxl, the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-21;

cxli. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-2;

cxlii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-15;

cxliii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-7;

cxliv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-28;

cxlv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-29;

cxlvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IFN-α;

cxlvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-21;

cxlviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-2;

cxlix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-15;

cl. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-7;

cli. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and

clii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-29;

cliii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IFN-α;

cliv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-21;

clv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-2;

clvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-15;

clvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-7;

clviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-28;

clix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-29;

clx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IFN-α;

clxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-21;

clxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-2;

clxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-15;

clxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-7;

clxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-28;

clxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-29;

clxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IFN-α;

clxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-21;

clxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-2;

clxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-15;

clxxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-7;

clxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-28;

clxxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-29;

clxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IFN-α;

clxxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-21;

clxxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-2;

clxxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-15;

clxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-7;

clxxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-28;

clxxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-29;

clxxxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IFN-α;

clxxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-21;

clxxxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and

clxxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-15;

clxxxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-7;

clxxxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-28;

clxxxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-29;

clxxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IFN-α;

clxxxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-21;

cxc. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-2;

cxci. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-15;

cxcii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-7;

cxciii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-28;

cxciv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-29;

cxcv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IFN-α;

cxcvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-21;

cxcvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-2;

cxcviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-15;

cxcix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and

cc. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-28;

cci. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-29;

ccii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IFN-α;

cciii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-21;

cciv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-2;

ccv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-15;

ccvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-7;

ccvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-28;

ccviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-29;

ccix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IFN-α;

ccx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-21;

ccxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-2;

ccxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-15;

ccxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-7;

ccxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-28;

ccxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-29;

ccxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IFN-α;

ccxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-21;

ccxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-2;

ccxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-15;

ccxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-7;

ccxxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-28;

ccxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-29;

ccxxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IFN-α;

ccxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-21;

ccxxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-2;

ccxxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-15;

ccxxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-7;

ccxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-28;

ccxxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-29;

ccxxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IFN-α;

ccxxxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and

ccxxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-2;

ccxxxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-15;

ccxxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-7;

ccxxxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-28;

ccxxxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-29;

ccxxxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IFN-α;

ccxxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-21;

ccxxxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-2;

ccxl, the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-15;

ccxli. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-7;

ccxlii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-28;

ccxliii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-29;

ccxliv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IFN-α;

ccxlv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-21;

ccxlvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-2;

ccxlvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and

ccxlviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-7;

ccxlix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-28;

ccl the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-29;

ccli. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IFN-α;

cclii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-21;

ccliii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-2;

ccliv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-15;

cclv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-7;

cclvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-28;

cclvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-29;

cclviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IFN-α;

cclix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-21;

cclx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-2;

cclxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-15;

cclxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-7;

cclxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-28;

cclxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-29;

cclxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IFN-α;

cclxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-21;

cclxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-2;

cclxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-15;

cclxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-7;

cclxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-28;

cclxxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-29;

cclxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IFN-α;

cclxxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-21;

cclxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-2;

cclxxv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-15;

cclxxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-7;

cclxxvii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-28;

cclxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-29;

cclxxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IFN-α;

cclxxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-21;

cclxxxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-4;

cclxxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-EGFR monoclonal antibody, and Z is IL-4;

cclxxxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-4;

cclxxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER2 monoclonal antibody, and Z is IL-4;

cclxxxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-4;

cclxxxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-4;

cclxxxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-4;

cclxxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-4;

cclxxxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-4;

ccxc. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GPC3 monoclonal antibody, and Z is IL-4;

ccxci. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-4;

ccxcii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PD-L1 monoclonal antibody, and Z is IL-4;

ccxciii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-4;

ccxciv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD19 monoclonal antibody, and Z is IL-4;

ccxcv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD20 monoclonal antibody, and

ccxcvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD20 monoclonal antibody, and Z is IL-4;

ccxcvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-4;

ccxcviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD22 monoclonal antibody, and Z is IL-4;

ccxcix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-4;

ccc. the IL-10 is SEQ ID No: 5, the second antibody is an anti-PSMA monoclonal antibody, and Z is IL-4;

ccci. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-4;

cccii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CEA monoclonal antibody, and Z is IL-4;

ccciii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-4;

ccciv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-BCMA monoclonal antibody, and Z is IL-4;

cccv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-4;

cccvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-gpA33 monoclonal antibody, and Z is IL-4;

cccvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-4;

cccviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CD33 monoclonal antibody, and Z is IL-4;

cccix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-4;

cccx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-DLL3 monoclonal antibody, and Z is IL-4;

cccxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-MUC17 monoclonal antibody, and

cccxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-MUC17 monoclonal antibody, and Z is IL-4;

cccxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-4;

cccxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-CLDN18 monoclonal antibody, and Z is IL-4;

cccxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-4;

cccxvi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-GD2 monoclonal antibody, and Z is IL-4;

cccxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-4;

cccxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-5T4 monoclonal antibody, and Z is IL-4;

cccxix. the IL-10 is SEQ ID No: 1, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-4;

cccxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-HER3 monoclonal antibody, and Z is IL-4;

cccxxi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-2;

cccxxii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-15;

cccxxiii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-7;

cccxxiv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-28;

cccxxv. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-29;

cccxxvi. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and Z is IFN-α;

cccxxvii. the IL-10 is SEQ ID No: 1, the second antibody is an anti-Ebola monoclonal antibody, and

cccxxviii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-2;

cccxxix. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-15;

cccxxx. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-7;

cccxxxi. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-28;

cccxxxii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-29;

cccxxxiii. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IFN-α; or

cccxxxiv. the IL-10 is SEQ ID No: 5, the second antibody is an anti-Ebola monoclonal antibody, and Z is IL-21.

cccxxxv.

2 . The method according to claim 1 , wherein the diakine further comprises a scFv targeting domain that targets a receptor different from the BiTE or CAR-T.

3 . The method according to claim 1 , wherein the second anti-Ebola antibody of any one of cccxxi. to cccxxxiv. is engrafted.

4 . The method according to claim 3 , wherein the second anti-Ebola antibody is engrafted with three CDRs from a VH and three CDRs from a VL obtained from a monoclonal antibody selected from CD3, CD4, CD5, CD7, CD14, CD25, CD30, CD34, CD38, CD40, CD47, CD52, CD56, CD70, CD79B, CD117, CD123, CD138, CD147, C-type lectin-like molecule-1 (CLL01), PD-1, TIM3, BTLA, latent membrane protein 1 (LMP-1), signal lymphocytic activation molecule F7 (SLAMF7), NY-ESO-1, transmembrane activator and CAML interactor (TACI), CS-1, CXCR4, NKG2D, B7-H3, LAG3, CTLA4, VEGFR1, EpCAM, mesothelin (MSO), PSCA, PSA, MUC1, Lewis-Y, AXL, Claudin 18.2, ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5, VCAM, FAPα, Trop2, EDB-FN, TGFβ, Trap, MAdCAM, 37 integrin subunit, α4β7 integrin, α4 integrin, SR-A1, SR-A3, SR-A4, SR-A5, SR-A6, SR-β, dSR-C1, SR-D1, SR-E1, SR-F1, SR-F2, SR-G, SR-H1, SR-H2, SR-11, SR-J1, or HIV.

5 . The method according to claim 1 , wherein the CAR-T or BiTE therapy targets hematological or solid tumors.

6 . The method according to claim 1 , wherein the CAR-T or BiTE targets an antigenic determinant selected from TNFRSF17, IL3RA, SDC1, CD5, CD19, CD20, CD22, CD23, CD33, CD38, CD44, CD70, CD133, CD174, CD274, CD276, CEACAM6, GFRA1, ITGB6, MS4A1, TNFRSF8, NCAM1, ULBP1, ULBP2, IL1RAP, CEACAM5, MET, EGFR, EGFRvIII, ENPP1, FGFR4, EPCAM, EPHA2, ERBB2, GPC3, MSLN, Muc1, PDCD1, KDR, IL13RA2, FOLH1, FAP, CA9, FOLR1, L1CAM, ROR1, SLAMF7, GD2, PSCA, GPNMB, CSPG4, or TEM1.

7 . The method according to claim 1 , wherein the CAR-T therapy is idecabtagene vicleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, tisagenlecleucel, or axicabtagene ciloleucel.